Merck to develop biosimilar of Pfizer's Enbrel | InPharm
Links shared publicly online about this topic.
- 218total visits
Merck to develop biosimilar of Pfizer's Enbrel | InPharm
View full resource at inpharm.com
Tags: Arthritis, Arthritis Medication, Rheumatoid Arthritis Medication, Drug, Healthy Aging, Enbrel, Pfizer, Merck & Co.
Most Recently Shared on June 15, 2011 at 7:00 am By:
Merck to develop biosimilar of Pfizer's Enbrel http://goo.gl/fb/lTiKk
Pfizer Makes Surprise Exit From Diabetes Deal With Indian Biotech - Forbes
forbes.com — “In October 2010, Pfizer announced a marketing alliance with Biocon, one of India's largest biotech firms, to develop generic (or biosimilar) versions of top-selling insulin products such as Eli Lilly's Humalog. Pfizer would pay $200 million upfront and $150 million in potential future milestones. Now, just fifteen months later, Pfizer [...]” View full resource at forbes.com
Most Recently Shared on March 13, 2012 at 10:34 am By:
Pfizer Makes Surprise Exit From Diabetes Deal With Indian Biotech - Forbes http://t.co/DlHlxXPf
No new drugs? Blame Wall Street - The Term Sheet: Fortune's deals blog Term Sheet
finance.fortune.cnn.com — “Big drugmakers are submitting to investors' short-sightedness instead of doing the right thing. FORTUNE -- Earlier this year, drug giant Pfizer (PFE) announced plans to slash spending on research and development by a third. Its shares closed that day up more than 5%. Two days later rival Merck (MRK) went the ...” View full resource at finance.fortune.cnn.com
Most Recently Shared on November 28, 2011 at 11:52 am By:
blogaceutics Pharma and Health Communicator
No new drugs? Blame Wall Street [CNNMoney] http://t.co/euknfsGT
Which Companies In The S&P Spend The Most In R&D? - Matthew Herper - The Medicine Show - Forbes
blogs.forbes.com — “Which companies in the S&P 500 spend the most on research and development? I asked the folks in our statistics department to run a screen to find out because I wanted to be able to compare research spending by pharmaceutical companies and that of the tech sector. The results come via [...]” View full resource at blogs.forbes.com
Most Recently Shared on July 28, 2011 at 6:47 pm By:
Drugs and Devices OW OW Health
Which Companies In The S&P Spend The Most In R&D?: Pfizer and Merck spend twice as much as Google. http://onforb.es/pzSXWh #drug
Merck & Co., Inc. and PAREXEL International Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates - News, Search Jobs, Events
biospace.com — “Merck & Co., Inc. and PAREXEL International Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates - News, Search Jobs, Events” View full resource at biospace.com
Most Recently Shared on January 12, 2011 at 3:58 pm By:
Scott Strumello Patient Expert
Merck & Co. & PAREXEL Int'l Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates http://bit.ly/fsKFIo
Merck & Co. in deal with Parexel to develop biosimilars - FirstWord
firstwordplus.com — “Merck & Co. in deal with Parexel to develop biosimilars - FirstWord” View full resource at firstwordplus.com
Most Recently Shared on January 12, 2011 at 1:28 pm By:
RT @fwpharma: Merck & Co. in deal with Parexel to develop biosimilars http://bit.ly/gWBK9I
AstraZeneca's CEO Poaches Pfizer, Chases Merck Ideal to Counter Failures - Bloomberg
bloomberg.com — “David Brennan couldn--™t sit still. During a meal of beef and potatoes at AstraZeneca Plc--™s drug research center near Stockholm in October, Brennan, the company--™s chief executive officer, grilled six drug-development managers over a concern raised by a laboratory scientist.” View full resource at bloomberg.com
Most Recently Shared on December 29, 2010 at 2:55 am By:
Bloomberg: AstraZeneca's CEO Poaches Pfizer, Chases Merck Ideal to Counter Failures. http://bit.ly/ezSKm0
Article > Pfizer shells out $350 million for insulin biosimilars
pharmatimes.com — “Article > Pfizer shells out $350 million for insulin biosimilars” View full resource at pharmatimes.com
Most Recently Shared on October 19, 2010 at 9:51 am By:
Pfizer distinct about developing its role in #diabetes http://bit.ly/8ZDPr7 via @PharmaTimes #hcsmeu #socpharm #hcsm
Pfizer enters deal on biosimilar insulin - NEWS - General articles - Pharmaceutical Industry - PMLiVE
pmlive.com — “Pharmaceutical Industry | NEWS | General | Pfizer enters deal on biosimilar insulin - Pfizer has entered into a deal with India-based biotech company Biocon for the global commercialisation of several Biocon biosimilars | PMLiVE” View full resource at pmlive.com
Most Recently Shared on October 18, 2010 at 5:03 pm By:
eyeonfda Pharma and Health Lawyer
RT @RAPSorg: Pfizer enters deal on biosimilar insulin - PMLiVE http://bit.ly/bTjgbV
Merck Shows Hurdles to Biotech Generics - WSJ.com
online.wsj.com — “A Merck decision to end efforts to copy an Amgen anemia drug shows how it won't be easy to develop biosimilars, or generic versions of biotechnology therapies.” View full resource at online.wsj.com
Most Recently Shared on May 16, 2010 at 11:09 pm By:
Merck Shows a Generics Hurdle http://on.wsj.com/dpM6qL
Merck To Move Ahead on a Heart Drug Where Pfizer Failed - Health Blog - WSJ
blogs.wsj.com — “Merck today highlighted cardiovascular pipeline with six molecules in late-stage development. Among them: anacetrapib -- a molecular cousin to a drug Pfizer once had in development.” View full resource at blogs.wsj.com
Most Recently Shared on May 11, 2010 at 5:23 pm By:
Merck To Move Ahead on a Heart Drug Where Pfizer Failed http://on.wsj.com/cuf7wt
FDA, Johnson & Johnson, Pfizer, Merck, And Novartis Present Best Practices At Adaptive Designs For Clinical Drug Development
medicalnewstoday.com — “Organized by Pharma IQ, a division of IQPC, the Adaptive Designs for Clinical Drug Development Summit will be held April 28-30, 2010 at the Ritz Carlton in Philadelphia, PA (” View full resource at medicalnewstoday.com
Most Recently Shared on April 17, 2010 at 4:27 am By:
MNT Clinical Trials Health News
FDA, Johnson & Johnson, Pfizer, Merck, And Novartis Present Best Practices At Adaptive Designs For Clinical Drug Devel... http://mnt.to/3Bnh
Advertisement
